Drugs / LYB004
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06874842 | Mar 2025 → Feb 2026 overdue | herpes zoster | Guangzhou Patronus Biotech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06335849 | Mar 2024 → Sep 2025 overdue | herpes zoster | Guangzhou Patronus Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07311148 | Oct 2025 → Jan 2026 overdue | herpes zoster | Guangzhou Patronus Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYB004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06335849 ↗ |
| Modality | Vaccine | “This phase 1 study in Australia will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years.” NCT06335849 ↗ |
| Route | Intramuscular | “LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.” NCT06335849 ↗ |